Inhibitor of p38 map kinase
A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 in the form of its maleate salt.
3. A compound according to claim 2 in the form of its Form 2 crystalline polymorph.
4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in combination with one or more pharmaceutically acceptable diluents or carriers.
5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in particulate form in combination with particulate lactose.
6. A pharmaceutical composition according to claim 5 further comprising particulate magnesium stearate.
7. A combination product comprising:
(A) a compound according to claim 1 ; and
(B) one or more other therapeutic agents,
wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
8. A method of treatment of a condition selected from COPD and asthma which comprises administering to a subject an effective amount of a compound according to claim 1 .
9. A pharmaceutical composition according to claim 4 wherein the compound of formula (I) is in the form of its maleate salt.
10. A pharmaceutical composition according to claim 5 wherein the compound of formula (I) is in the form of its maleate salt.
11. A pharmaceutical composition according to claim 6 wherein the compound of formula (I) is in the form of its maleate salt.
12. A combination product according to claim 7 wherein the compound of formula (I) is in the form of its maleate salt.
13. A method according to claim 8 wherein the compound of formula (I) is in the form of its maleate salt.
14. A pharmaceutical composition according to claim 9 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.
15. A pharmaceutical composition according to claim 10 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.
16. A pharmaceutical composition according to claim 11 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.
17. A combination product according to claim 12 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.
18. A method according to claim 13 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.